Shelton Capital Management Bluebird Bio, Inc. Transaction History
Shelton Capital Management
- $3.99 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding BLUE
# of Institutions
32Shares Held
27MCall Options Held
191KPut Options Held
299K-
Black Rock Inc. New York, NY15.4MShares$112 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$33.9 Million0.02% of portfolio
-
Colony Group LLC Boston, MA41.9KShares$304,9180.0% of portfolio
-
Connacht Asset Management LP New York, NY31.6KShares$229,9790.59% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL28.7KShares$208,7210.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $561M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...